Great Point Partners

Great Point Partners (GPP) is a Greenwich, Connecticut-based private equity firm with a dedicated focus on the healthcare industry. Established with a mission to partner with management teams to build successful healthcare companies, GPP primarily engages in growth equity and buyout investments. The firm's strategy revolves around identifying profitable healthcare businesses that are poised for significant expansion, leveraging its deep sector expertise and extensive network to drive value creation. GPP manages capital on behalf of a diverse base of institutional investors, including endowments, foundations, and family offices, underscoring its established presence in the private equity landscape.

GPP's investment thesis centers on supporting companies across various sub-sectors within healthcare, including biopharmaceutical services, healthcare IT, medical devices, and specialty pharmaceuticals. They seek to invest in businesses with strong fundamentals, proven business models, and significant growth potential, often through organic expansion, strategic acquisitions, and operational enhancements. The firm emphasizes a collaborative approach, working closely with portfolio company management to implement growth strategies, optimize operations, and navigate complex market dynamics, thereby aiming to accelerate market leadership and generate substantial returns.

The firm has a robust history of successful fundraises, demonstrating consistent investor confidence. Their most recent fund, Great Point Partners V, closed in 2022 with total commitments of $507 million, significantly exceeding its predecessor funds and reflecting strong demand from both new and existing limited partners. Typically, Great Point Partners makes equity investments ranging from $10 million to $100 million per transaction, targeting profitable companies that can benefit from their strategic guidance and capital injection. This range positions them to support a wide array of growth-stage and middle-market healthcare businesses.